The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.